|
1
|
Zhou J, Li J, Wang Z, Yin C and Zhang W:
Metadherin is a novel prognostic marker for bladder cancer
progression and overall patient survival. Asia Pac J Clin Oncol.
8:e42–e48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Denzinger S, Mohren K, Knuechel R, Wild
PJ, Burger M, Wieland WF, Hartmann A and Stoehr R: Improved
clonality analysis of multifocal bladder tumors by combination of
histopathologic organ mapping, loss of heterozygosity, fluorescence
in situ hybridization, and p53 analyses. Hum Pathol. 37:143–151.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marr BP, Hung C, Gobin YP, Dunkel IJ,
Brodie SE and Abramson DH: Success of intra-arterial chemotherapy
(chemo-surgery) for retinoblastoma: Effect of orbitovascular
anatomy. Arch Ophthalmol. 130:180–185. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang P, Chen J, Wang L, Na Y, Kaku H,
Ueki H, Sasaki K, Yamaguchi K, Zhang K, Saika T, et al:
Implications of transcriptional factor, OCT-4, in human bladder
malignancy and tumor recurrence. Med Oncol. 29:829–834. 2012.
View Article : Google Scholar
|
|
6
|
Munier FL, Gaillard M-C, Balmer A, Soliman
S, Podilsky G, Moulin AP and Beck-Popovic M: Intravitreal
chemotherapy for vitreous disease in retinoblastoma revisited: From
prohibition to conditional indications. Br J Ophthalmol.
96:1078–1083. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shields CL, Shelil A, Cater J, Meadows AT
and Shields JA: Development of new retinoblastomas after 6 cycles
of chemo-reduction for retinoblastoma in 162 eyes of 106
consecutive patients. Arch Ophthalmol. 121:1571–1576. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shields CL, Palamar M, Sharma P,
Ramasubramanian A, Leahey A, Meadows AT and Shields JA:
Retinoblastoma regression patterns following chemoreduction and
adjuvant therapy in 557 tumors. Arch Ophthalmol. 127:282–290. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ziebold U, Reza T, Caron A and Lees JA:
E2F3 contributes both to the inappropriate proliferation and to the
apoptosis arising in Rb mutant embryos. Genes Dev. 15:386–391.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schleicher SM, Moretti L, Varki V and Lu
B: Progress in the unraveling of the endoplasmic reticulum
stress/autophagy pathway and cancer: Implications for future
therapeutic approaches. Drug Resist Updat. 13:79–86. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park WH, Kim ES, Kim BK and Lee YY:
Monensin-mediated growth inhibition in NCI-H929 myeloma cells via
cell cycle arrest and apoptosis. Int J Oncol. 23:197–204.
2003.PubMed/NCBI
|
|
12
|
Robinson SM, Tsueng G, Sin J, Mangale V,
Rahawi S, McIntyre LL, Williams W, Kha N, Cruz C, Hancock BM, et
al: Coxsackievirus B exits the host cell in shed microvesicles
displaying autophagosomal markers. PLoS Pathog. 10:e10040452014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nishino I: Autophagic vacuolar myopathy.
Semin Pediatr Neurol. 13:90–95. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Park MA, Zhang G, Martin AP, Hamed H,
Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, Liu X, et al:
Vorinostat and sorafenib increase ER stress, autophagy and
apoptosis via ceramide-dependent CD95 and PERK activation. Cancer
Biol Ther. 7:1648–1662. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang L, Meng Y, Bao C, Liu W, Ma C, Li A,
Xuan Z, Shan G and Jia Y: Robustness and backbone motif of a cancer
network regulated by miR-17-92 cluster during the G1/S
transition. PLoS One. 8:e570092013. View Article : Google Scholar
|
|
16
|
Baldi A, De Luca A, Claudio PP, Baldi F,
Giordano GG, Tommasino M, Paggi MG and Giordano A: The RB2/p130
gene product is a nuclear protein whose phosphorylation is cell
cycle regulated. J Cell Biochem. 59:402–408. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cao C, Subhawong T, Albert JM, Kim KW,
Geng L, Sekhar KR, Gi YJ and Lu B: Inhibition of mammalian target
of rapamycin or apoptotic pathway induces autophagy and
radiosensitizes PTEN null prostate cancer cells. Cancer Res.
66:10040–10047. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He Z, Zhang Y, Mehta SK, Pierson DL, Wu H
and Rohde LH: Expression profile of apoptosis related genes and
radio-sensitivity of prostate cancer cells. J Radiat Res (Tokyo).
52:743–751. 2011. View Article : Google Scholar
|
|
19
|
Shimizu S, Kanaseki T, Mizushima N, Mizuta
T, Arakawa-Kobayashi S, Thompson CB and Tsujimoto Y: Role of Bcl-2
family proteins in a non-apoptotic programmed cell death dependent
on autophagy genes. Nat Cell Biol. 6:1221–1228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ondrousková E, Soucek K, Horváth V and
Smarda J: Alternative pathways of programmed cell death are
activated in cells with defective caspase-dependent apoptosis. Leuk
Res. 32:599–609. 2008. View Article : Google Scholar
|
|
21
|
Matsuoka M, Kurita M, Sudo H, Mizumoto K,
Nishimoto I and Ogata E: Multiple domains of the mouse
p19ARF tumor suppressor are involved in p53-independent
apoptosis. Biochem Biophys Res Commun. 301:1000–1010. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Paliwal S, Pande S, Kovi RC, Sharpless NE,
Bardeesy N and Grossman SR: Targeting of C-terminal binding protein
(CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol.
26:2360–2372. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mitra AP, Hansel DE and Cote RJ:
Prognostic value of cell-cycle regulation biomarkers in bladder
cancer. Semin Oncol. 39:524–533. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eruslanov E, Neuberger M, Daurkin I,
Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM and
Kusmartsev S: Circulating and tumor-infiltrating myeloid cell
subsets in patients with bladder cancer. Int J Cancer.
130:1109–1119. 2012. View Article : Google Scholar
|
|
25
|
Urquidi V, Kim J, Chang M, Dai Y, Rosser
CJ and Goodison S: CCL18 in a multiplex urine-based assay for the
detection of bladder cancer. PLoS One. 7:e377972012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kaufman DS, Shipley WU and Feldman AS:
Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tanaka N, Ogi K, Odajima T, Dehari H,
Yamada S, Sonoda T and Kohama G: pRb2/p130 protein expression is
correlated with clinicopathologic findings in patients with oral
squamous cell carcinoma. Cancer. 92:2117–2125. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kunze D, Wuttig D, Fuessel S, Kraemer K,
Kotzsch M, Meye A, Grimm MO, Hakenberg OW and Wirth MP: Multitarget
siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in
bladder cancer cells. Anticancer Res. 28(4B): 2259–2263.
2008.PubMed/NCBI
|
|
29
|
Wang YB, Qin J, Zheng XY, Bai Y, Yang K
and Xie LP: Diallyl trisulfide induces Bcl-2 and
caspase-3-dependent apoptosis via downregulation of Akt
phosphorylation in human T24 bladder cancer cells. Phytomedicine.
17:363–368. 2010. View Article : Google Scholar
|
|
30
|
Yo YT, Shieh GS, Hsu KF, Wu CL and Shiau
AL: Licorice and licochalcone-A induce autophagy in LNCaP prostate
cancer cells by suppression of Bcl-2 expression and the mTOR
pathway. J Agric Food Chem. 57:8266–8273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Siegel PM and Massagué J: Cytostatic and
apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev
Cancer. 3:807–821. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Candé C, Cohen I, Daugas E, Ravagnan L,
Larochette N, Zamzami N and Kroemer G: Apoptosis-inducing factor
(AIF): A novel caspase-independent death effector released from
mitochondria. Biochimie. 84:215–222. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu X, Cai ZD, Lou LM and Zhu YB:
Expressions of p53, c-MYC, BCL-2 and apoptotic index in human
osteosarcoma and their correlations with prognosis of patients.
Cancer Epidemiol. 36:212–216. 2012. View Article : Google Scholar
|
|
34
|
Mojtahedi Z, Hashemi SB, Khademi B, Karimi
M, Haghshenas MR, Fattahi MJ and Ghaderi A: p53 codon 72
polymorphism association with head and neck squamous cell
carcinoma. Braz J Otorhinolaryngol. 76:316–320. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang L, Wang C, Lei F, Zhang L, Zhang X,
Liu A, Wu G, Zhu J and Song L: miR-93 promotes cell proliferation
in gliomas through activation of PI3K/Akt signaling pathway.
Oncotarget. 6:8286–8299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cooper CS, Nicholson AG, Foster C, Dodson
A, Edwards S, Fletcher A, Roe T, Clark J, Joshi A, Norman A, et al:
Nuclear overexpression of the E2F3 transcription factor in human
lung cancer. Lung Cancer. 54:155–162. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Foster CS, Falconer A, Dodson AR, Norman
AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar
S, et al: Transcription factor E2F3 overexpressed in prostate
cancer independently predicts clinical outcome. Oncogene.
23:5871–5879. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin HY, Huang CH, Wu WJ, Chou YH, Fan PL
and Lung FW: Mutation of the p53 tumor suppressor gene in
transitional cell carcinoma of the urinary tract in Taiwan.
Kaohsiung J Med Sci. 21:57–64. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cheng GZ, Park S, Shu S, He L, Kong W,
Zhang W, Yuan Z, Wang LH and Cheng JQ: Advances of AKT pathway in
human oncogenesis and as a target for anti-cancer drug discovery.
Curr Cancer Drug Targets. 8:2–6. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
